Regeneron: 3 Key Takeaways for Long-Term Investors

Impact · against what's priced in

The Q3 revenue beat and Eylea HD transition confirm current growth trajectories but do not shift the long-term valuation crux. The early-stage CIDEB results provide a new, albeit speculative, catalyst for diversification beyond the current product mix.

REGN+0.20

Challenges what's priced in

The price assumes

Any upside from the olatorepatide obesity and diabetes studies, which the market treats as a free option

The market currently treats pipeline upside as a free option; the successful early-stage trial of the CIDEB liver therapy provides a concrete, new data point for non-Dupixent revenue diversification.

What REGN's price assumes · Sep 12

• REGNNew
• earnings▲13%
• revenue growth
• healthcare
• pharmaceuticals
• biotech
• SNY
• clinical trials